Sarepta Therapeutics Inc Q4 2021 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Gil Joseph Blum - Needham & Company, LLC, Research Division - Analyst : So maybe focusing a little on the PPMOs here. So you guys have never taken a price increase on your PMO franchise. But considering the potential for an improved clinical benefit of 5051, would there be discussions around this? Is this even something you're considering?

Question: Yun Zhong - BTIG, LLC, Research Division - Analyst : So my question is a follow-up one on PPMO platform. And with a better clinical profile, how possible do you think the platform can potentially expand the patient population, convincing those patients who are not committed to receiving exon skipping therapies to get on treatment? And given that you said that EXONDYS 51 and maybe even VYONDYS 53, the sales are nearing plateauing. So if you -- I know that you are very confident in the gene therapy program, but if you do decide to work on additional candidates, how fast do you think you can move the next one into the clinic?

Question: Zhiqiang Shu - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : I want to ask about your 2025 revenue aspiration of $4 billion. I think you just look at the consensus right now is $2.2 billion, $2.3 billion. What do you think the Street is missing here? And what do you think that the delta can be accounted for?